BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month
Latest product candidate reaffirms growth opportunities for hydrophilic topical delivery system
MENLO PARK, Calif., Jan. 12, 2018 -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present to the medical community preliminary data from the treatment of rosacea using its novel topical gel, BPX-04.
BPX-04 is the company’s latest addition to its clinical pipeline. It is the second product built on the proprietary, patent-pending BioPharmX hydrophilic topical delivery system. BPX-04 reinforces the value of the unique delivery system as BioPharmX researchers explore other applications.
BioPharmX presentations will include:
“Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study,” which will be presented at the Winter Clinical Dermatology Conference – Hawaii, Jan. 12-17. The poster will show that clinically meaningful improvements were reported after just four weeks of treatment.
“Cutaneous Tolerability of a Novel Topical Minocycline Gel for the Treatment of Rosacea,” which will be presented at Maui Derm for Dermatologists 2018 conference, Jan. 28-Feb. 1. The poster will show that most subject ratings for burning, stinging, tightness and itching improved or were unchanged.
"The promise of BPX-04 continues to reinforce the value of our topical delivery system and its ability to deliver new therapies for multiple indications,” said Anja Krammer, co-founder and president of BioPharmX. “These presentations allow us to fulfill the demand for information about our research and communicate results of promising topical therapies to physicians.”
In addition, BioPharmX will be highlighted in discussions of emerging therapies, featuring BPX-01 for acne and BPX-04 for rosacea:
Winter Clinical Derm Conference Hawaii, Maui – January 12-17
"What's New in Topical Therapy," a presentation by Dr. Linda Stein-Gold Jan. 14, 10:45 a.m.
"What's New in Medicine Chest, Part 2," a presentation by Dr. Jim Del Rosso Jan. 15, 9:40a.m.
“New Developments in Topical Therapies,” a presentation by Dr.s Jim Del Rosso, Linda Stein-Gold and Joshua Zeichner Jan 16, 9:30 a.m.
"What's New & Coming in Therapeutics," a second presentation by Dr. Del Rosso Jan. 17, 1 p.m.
MauiDerm2018, Wailea – January 28-February 1
“Acne and Rosacea,” a session moderated by Dr. Guy Webster Jan. 31, 7:30-8:45 a.m.
Oral minocycline has been widely used since the 1970s, however oral antibiotics tend to flood the body with medicine and are associated with adverse effects that range from nausea to diarrhea. There is also growing concern over the rise in antibiotic-resistant bacteria. Despite results that show minocycline produces less resistance than other tetracycline-class antibiotics (e.g. doxycycline and tetracycline) in oral form, the pharmaceutical industry has not brought to market any stable, soluble topical formulations of minocycline. BioPharmX has developed a topical gel formulation of minocycline that reaches areas of the skin, where acne, rosacea, and other conditions develop. By applying minocycline topically, systemic uptake of minocycline is reduced relative to oral delivery and thus the drug’s beneficial effects are focused in the skin where P.acnes bacteria are located.
BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3 trials. The company is currently conducting a pilot clinical study for BPX-04 and is preparing for a phase 2 trial.
